Provider Statement: This continuing medical education activity is provided by .

Support Statement: This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Target Audience: The intended audience for this activity is medical oncologists, radiology oncologists, surgical oncologists, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Assess new evidence about the clinical utility of emerging immunotherapeutic agents in the treatment of non-small cell lung cancer.

Examine the latest safety and quality-of-life data from clinical trials utilizing immunotherapies in non-small cell lung cancer to aid in increasing physician awareness about these novel approaches and enable incorporation of these strategies in future practice.

Activity Chair:

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology)

Professor of Pharmacology, Chief of Medical Oncology

Director, Thoracic Oncology Research Program

Associate Director for Translational Research, Translational Research Program

Yale Comprehensive Cancer Center

Yale School of Medicine

New Haven, CT

Faculty:

Julie Renee Brahmer, MD, MSc

Associate Professor of Oncology

Director, Thoracic Oncology Program

Johns Hopkins Kimmel Cancer Center

Baltimore, MD

Edward B. Garon, MD, MS

Associate Clinical Professor of Hematology/Oncology

The David Geffen School of Medicine at UCLA

Director, Thoracic Oncology Program

UCLA’s Jonsson Comprehensive Cancer Center

Los Angeles, CA

Reviewers:

Joel W. Neal, MD, PhD

Ronald A. Codario, MD, FACP, FNLA, CCMEP

Accreditation:

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, July 29, 2015, through July 28, 2016.

How To Participate in this Activity and Obtain CME Credit:

To participate in this CME activity, you must read the objectives, answer pretest question, view content, complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures:

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Faculty members report the following relationship(s):

Roy S. Herbst, MD, PhD

Served as an advisor or consultant for: Biothera, Diatech, Genentech/Roche, Gilead, Kolltan, Merck, N of 1, Pfizer

Received grants for clinical research from: Genentech

Julie Renee Brahmer, MD, MSc

Served as an advisor or consultant for: Bristol-Myers Squibb, Celgene, Eli Lilly, Merck

Received grants for clinical research from: Bristol-Myers Squibb, MedImmune/AstraZeneca, Merck

Edward B. Garon, MD, MS

Received grants for clinical research from: AstraZeneca, Bristol-Myers Squib, Eli Lilly, Genentech, Merck, Novartis, Pfizer, Puma

Reviewers report the following relationship(s):

Joel W. Neal, MD, PhD

Served as an advisor or consultant for: CARET Physicians Resource Management , Clovis Oncology, Nektar Therapeutics

Received grants for clinical research from: ArQule, Boehringer Ingelheim, Exelixis, Genentech/Roche, Merck , Nektar Therapeutics, Novartis

Ronald A. Codario, MD, FACP, FNLA, CCMEP

No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com